Abstract Fibrosis is a fundamental component of the adverse structural remodeling of myocardium present in the failing heart. Replacement fibrosis appears at sites of previous cardiomyocyte necrosis to preserve the structural integrity of the myocardium, but not without adverse functional consequences. The extensive nature of this microscopic scarring suggests cardiomyocyte necrosis is widespread and the loss of these contractile elements, combined with fibrous tissue deposition in the form of a stiff in-series and in-parallel elastic elements, contributes to the progressive failure of this normally efficient muscular pump. Cellular and molecular studies into the signaltransducer-effector pathway involved in cardiomyocyte necrosis have identified the crucial pathogenic role of intracellular Ca 2? overloading and subsequent induction of oxidative stress, predominantly confined within its mitochondria, to be followed by the opening of the mitochondrial permeability transition pore that leads to the destruction of these organelles and cells. It is now further recognized that Ca 2? overloading of cardiac myocytes and mitochondria serves as a prooxidant and which is counterbalanced by an intrinsically coupled Zn 2? entry serving as antioxidant. The prospect of raising antioxidant defenses by increasing intracellular Zn 2? with adjuvant nutriceuticals can, therefore, be preferentially exploited to uncouple this intrinsically coupled Ca 2? -Zn 2? dyshomeostasis. Hence, novel yet simple cardioprotective strategies may be at hand that deserve to be further explored. 
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Introduction
Fibrosis, including microscopic scarring, is a fundamental component of the adverse structural remodeling found in the myocardium of the failing human heart [1, 2] . Scarring, a morphologic footprint of earlier cardiomyocyte necrosis, serves to replace lost contractile cells and thereby plays a vital role in preserving myocardial structure and function. The extensive distribution of this replacement fibrosis suggests a widespread and ongoing necrosis of cardiomyocytes. Apoptosis also occurs in the failing heart, but to a lesser extent, often involving such noncardiomyocytes as macrophages and endothelial cells [3] . Furthermore, programmed cell death begets neither inflammatory cells nor fibroblast responses. As a consequence, fibrous tissue does not appear at the site of lost myocytes and, therefore, apoptosis has been referred to as a sterile form of cell death [4, 5] . The cumulative loss of contractile elements, together with the deposition of fibrous tissue, stiff in-series and in-parallel elastic elements composed primarily of type I fibrillar collagen having the tensile strength of steel, each contributes to the progressive failure of this previously efficient muscular pump during systolic and/ or diastolic phases of the cardiac cycle [6] . Elevations in serum troponins, which do not stem from an acute coronary event or significant renal dysfunction, that compromises urinary troponin excretion have been reported in patients hospitalized because of the symptoms and signs of congestive heart failure (CHF) [7] [8] [9] [10] [11] [12] [13] [14] [15] . This would be consistent with an ongoing necrotic loss of cardiomyocytes. Coronary microembolization with microinfarcts could be held responsible for the rise in serum troponins [16] . We speculate neurohormonal activation could be another plausible mechanism. In either case, these serum-derived biomarkers of cardiomyocyte necrosis are associated with increased in-hospital and overall cardiac morbidity and mortality. Insights into cellular and molecular pathways involved in ongoing cardiomyocyte necrosis are quintessential in developing novel cardioprotective strategies that would salvage them and prevent myocardial fibrosis.
The failing heart and congestive heart failure syndrome
The heart fails as the contractility of this muscular pump declines and it becomes unable to propel sufficient amounts of blood and nutrients into the circulation for their delivery to metabolizing tissues at a rate commensurate with their prevailing metabolic demands. Likewise, the heart also fails when its ability to receive blood during diastolic filling is compromised by abnormalities in myocardial relaxation and/or tissue stiffness, and consequently atrial and ventricular filling pressures are inappropriately elevated and the displacement of blood is suboptimal due to the inadequately stretched ventricle. Systemic blood flow can, therefore, be impaired by ventricular dysfunction in either systole or diastole. In turn, renal perfusion is correspondingly reduced setting the primary prerequisite for the appearance of CHF.
In order to sustain a steady-state filtration fraction at equilibrium over a wide range of conditions where the intake of water is either plentiful or limited, renal blood flow normally constitutes 20% of the cardiac output. However, when renal perfusion is reduced, juxtaglomerular cells elaborate renin leading to an ensuing activation of the renin-angiotensin-aldosterone system (RAAS). A concomitant activation of the hypothalamic-pituitary-adrenal (HPA) axis stimulates the adrenergic nervous system (ANS) and release of catecholamines. The HPA axis also contributes to adrenocorticotropin (ACTH)-mediated release of glucocorticoids and mineralocorticoids by the adrenal glands. Activation of the RAAS and ANS normally involves short-term, physiologic homeostatic responses to reduced dietary Na ? intake or intravascular volume contraction. In the patient with heart failure, however, sustained homeostatic neurohormonal responses beget dyshomeostasis, which over time is expressed as an inappropriate (relative to dietary Na ? and intravascular volume) salt-avid state. The accompanying retention of salt and water, and subsequent expansion of intra-and later extravascular volumes, leads to the symptoms and signs of the clinical syndrome CHF. CHF occurs when these homeostatic responses are inappropriate and persistent. Treatment of the decompensated, often-hospitalized, patient with CHF will restore euvolemia and ameliorate their signs and symptoms returning them to a state of compensation. Episodes of neurohormonal activation that beget CHF disrupt the stable state of compensation and as such represent an acute stressor state, which proves integral to the pathologic remodeling of myocardium. Less well recognized are adverse consequences of effector hormones of the RAAS and ANS that extend beyond salt and water retention to involve a dyshomeostasis of several cations, including K , and Zn 2? , which have been shown to adversely influence intracellular homeostasis and survival of cardiomyocytes [17] [18] [19] [20] [21] .
Acute stressor state
Bodily injury, such as accompanies burns, head trauma, subarachnoid hemorrhage, or acute myocardial infarction, represents a hyperadrenergic acute stressor state with marked elevations in circulating catecholamines. Acting through b2 receptors, epinephrine and norepinephrine promote the translocation of K
? from blood into the intracellular compartment of various cells, including cardiac myocytes and peripheral blood mononuclear cells (PBMC), leading to hypokalemia [22] [23] [24] . Likewise, plasma-ionized hypocalcemia and hypomagnesemia, and hypozincemia are common findings at the time of or soon after admission in patients hospitalized in the medical/ surgical intensive care unit or the coronary care unit [25, 26] . The magnitude to which their respective plasma concentrations fall correlates well with the severity of injury, and therefore they may have predictive roles as relevant clinical biomarkers of poor prognosis. Necrosis of cardiomyocytes, with an elevation in serum troponins (albeit modest vis-à-vis myocardial infarction), occurs in response to the marked rise in circulating catecholamines and which can be ascertained postmortem from the morphologic evidence of contraction band necrosis and microscopic scarring of the right and left heart.
Acute stressor state: an animal model
The cellular and molecular pathways leading to this adverse myocardial remodeling during the systemic hyperadrenergic state have been investigated in animal models. In rodents, the administration of a single dose of a catecholamine leads to acute intracellular Ca 2? overloading of cardiac myocytes and mitochondria, as well as the concomitant generation of reactive oxygen and nitrogen species that overwhelm antioxidant defenses [27] . Cardiomyocyte necrosis, for example, occurs within hours of isoproterenol infusion and can be prevented by cotreatment with either a b 1 adrenergic receptor antagonist or Ca 2? channel blocker [20, 21, 28 intake. Drinking water is fortified with 1% NaCl and 0.4% KCl to prevent hypokalemia. At week 1 of aldosterone/salt treatment (ALDOST), animals are clinically healthy and the myocardium appears normal by light microscopy. This preclinical stage gives way to a clinical stage with anorexia and a failure to gain weight at week 2 and beyond. Cardiac pathology first appears at week 4. This pathologic stage features microscopic scarring scattered throughout both the right and left atria and ventricles [49] . A perivascular/interstitial fibrosis involving the coronary, renal, and mesenteric circulations is also found. This topic has been reviewed extensively elsewhere [50, 51] .
A series of studies have addressed the relevance of hemodynamic factors that could potentially contribute to cardiac fibrosis and have concluded those are not directly involved (reviewed in [52] ). This viewpoint was primarily based on: (a) the presence of fibrosis in nonpressureoverloaded right atria and ventricle; (b) the absence of fibrosis when the LV pressure overload is created by infrarenal aortic banding without subsequent RAAS activation or when treatment is based on aldosterone together with a low-Na ? diet, or when 1% NaCl alone is given; (c) the prevention of fibrosis with either a small (nondepressor) or large (depressor) dose of spironolactone, which respectively fails to or does prevent hypertension; (d) an intracerebroventricular infusion of a mineralocorticoid receptor antagonist that prevents hypertension, but not fibrosis [53]; and (e) when a cardiospecific upregulation of aldosterone synthase accounts for increased tissue levels of aldosterone unaccompanied by cardiac fibrosis [54] . Thus, the evidence gathered to date indicates the adverse remodeling of myocardium during ALDOST is both (a) independent of hypertension and (b) unrelated to plasma or tissue-derived aldosterone per se, but some other circulating factor that accompanies aldosteronism (vide infra).
Cellular and molecular pathways leading to cardiomyocyte necrosis
Pathways accounting for cardiomyocyte necrosis and subsequent scarring of myocardium found at 4 weeks ALDOST have been examined and the identity and pathogenic role of circulating factors elucidated.
Oxidative stress
Evidence of oxidative stress in the myocardium is found during chronic mineralocorticoidism [55] [56] [57] [58] [59] . This includes (a) the presence of 3-nitrotyrosine, a byproduct of the reaction involving superoxide and nitric oxide; (b) an activation of the gp91 phox subunit of NADPH oxidase found in inflammatory cells invading the injured myocardium that contributes to superoxide generation; (c) upregulated redox-sensitive nuclear transcription factor (NF)-jB and a proinflammatory gene cascade it regulates that includes intercellular adhesion molecule (ICAM)-1, monocyte chemoattractant protein (MCP)-1, and tumor necrosis factor (TNF)-alpha; and (d) increased tissue levels of 8-isoprostane and malondialdehyde, biomarkers of lipid peroxidation [58, 59] . There is also considerable evidence of oxidative stress in blood and urine consistent with the systemic nature of an altered redox state during chronic aldosteronism.
Intracellular Ca 2? overloading
Our hypothesis for the induction of oxidative stress during ALDOST would draw upon Albrecht Fleckenstein's original concept that intracellular Ca 2? overloading of the heart is an integral and adverse pathophysiologic feature leading to myocardial necrosis [60] . In rats receiving 1 and 4 weeks ALDOST, we monitored intracellular Ca 2? levels in several tissues that included the heart and PBMC. We found increased Ca 2? levels in the myocardium and PBMC during preclinical, clinical, and pathologic stages, accompanied by biomarker evidence of oxidative stress that included increased levels of malondialdehyde and 8-isoprostane in the heart and increased H 2 O 2 production by PBMC [59, [61] [62] [63] , in fact, is manyfold greater than their urinary losses [61] .
Secondary hyperparathyroidism (SHPT)
Metabolic studies accounted for the marked increase in urinary and fecal excretion of Ca 2? and Mg 2? during ALDOST, which leads to plasma-ionized hypocalcemia and hypomagnesemia. The calcium-sensing receptor of the parathyroid glands, in turn, responds to hypocalcemia with increased secretion of PTH. Accordingly, plasma PTH levels rise [61] and SHPT is evidenced by marked and progressive reductions in bone mineral density and bone strength [64] . We therefore hypothesized the intracellular Ca 2? overloading and induction of oxidative stress that accompanies ALDOST leading to cardiomyocyte necrosis, and scarring is mediated by the calcitropic hormone, PTH and not aldosterone (see Fig. 1 ). It represents an example of the Ca 2? paradox associated with SHPT as characterized by Fujita and Palmieri [65] . Furthermore, PTH-mediated intracellular Ca 2? overloading is coupled to an induction of oxidative stress in diverse tissues that includes cardiomyocytes and their mitochondria, as well as PBMC. The generation of reactive oxygen (ROS) and nitrogen (RNS) species appear to overwhelm their rate of detoxification by the cumulative capacity of antioxidant defenses. In mitochondria, Ca 2? overloading and oxidative stress lead to a nonphysiologic opening of the mPTP, with the ensuing osmotic-based structural and functional degeneration of these organelles that triggers the downhill final common cell death pathway leading to cardiomyocyte necrosis and subsequent replacement fibrosis [66] .
A series of site-directed, sequential pharmacologic interventions targeted along the cellular-molecular cascades to block downstream events leading to cardiomyocyte necrosis and myocardial scarring were conducted. They collectively validated our hypothesis regarding the pathologic sequelae of events leading to this structural remodeling of myocardium in rats with chronic aldosteronism. These interventions included (a) cotreatment with spironolactone, an aldosterone receptor antagonist that attenuated the enhanced urinary and fecal losses of these cations to prevent hypocalcemia and hypomagnesemia and thereby ensuing SHPT [61] ; (b) cotreatment with a Ca 2? -and Mg 2? -supplemented diet, together with vitamin D 3 to enhance Ca 2? absorption, which prevented hypocalcemia and SHPT [67] ; (c) parathyroidectomy, performed prior to starting ALDOST, to prevent SHPT [68] ; (d) cotreatment with cinacalcet, a calcimimetic that resets the threshold of the parathyroid glands' Ca 2? -sensing receptor to prevent SHPT despite modest hypocalcemia [69] ; (e)cotreatment with amlodipine, a Ca 2? channel blocker, which prevents intracellular Ca 2? overloading [62] ; and finally (f) cotreatment with N-acetylcysteine, an antioxidant that abrogated oxidative stress [58] .
Thus, taken together, the multitude of evidence gathered to date congruently supports the mechanism of PTHmediated intracellular Ca 2? overloading that leads to the induction of oxidative stress during aldosteronism where ROS and RNS, primarily derived from mitochondria, overwhelm cellular antioxidant defenses. This scenario anticipates whether the overall consequence of an excessive generation of prooxidants or cumulative endogenous antioxidant defenses in combating ROS and RNS had been compromised. In this context, we next addressed plausible association of Zn 2? dyshomeostasis during ALDOST given its importance to these endogenous defenses, including Cu/Zn-superoxide dismutase (SOD).
Zinc dyshomeostasis
Chronic inappropriate excess of aldosterone is accompanied by increased urinary and fecal excretory Zn 2? losses, hypozincemia, and a fall in plasma Cu/Zn-SOD activity [70] . The hyperzincuria seen with ALDOST is related to urinary acidification, which contributes to the consequent metabolic alkalosis of aldosteronism [59] . Also contributory to hypozincemia is a coordinated selective translocation of Zn 2? to the sites of tissue injury, facilitated by corresponding upregulation of a Zn 2? -binding protein, metallothionein (MT)-1 in targeted tissues [59, 70] .
We also used a 65 Zn tracer to systematically monitor Zn 2? kinetics during 1 and 4 weeks of ALDOST. A simultaneous fall in plasma 65 Zn and a selective accumulation of 65 Zn was found at sites of injury that included its translocation to recently incised skin at week 1 used for osmotic minipump implantation, as well as the injured heart and kidneys at week 4. This intracellular trafficking of 65 Zn to injured tissues was facilitated by the upregulation of MT-1 [71] . However, at week 4, there was a decline in 65 Zn in healed skin and bone, which serve as Zn 2? reservoirs and participate in resolving acute hypozincemia. Thus, the preferential translocation of circulating Zn 2? to injured tissues contributes to hypozincemia found with ALDOST, where increased tissue Zn 2? is essential in wound healing at these sites [72] , and the consequent appearance of plasma-ionized hypocalcemia and hypomagnesemia. Elevations in parathyroid hormone (PTH) seek to restore extracellular homeostasis of these divalent cations through their resorption from bone, absorption from gut, and reabsorption by kidney promoted by the steroid hormone 1,25(OH) 2 D 3 . Paradoxically, PTH elaboration is responsible for intracellular Ca 2? overloading and the induction of oxi-/nitrosative stress, which leads to cardiomyocyte necrosis and consequent replacement fibrosis, or scarring. Adapted from Alsafwah et al. [115] Heart The dyshomeostasis of extra-and intracellular Ca 2? and Zn 2? that accompanies ALDOST contributes to a deleterious but reversible dysequilibrium between pro-and antioxidants. We hypothesized that intrinsic coupling of intracellular Ca 2? and Zn 2? dyshomeostasis regulates the redox state of cardiac myocytes and mitochondria. To test our hypothesis, we monitored each of these two cations using relevant fluorescent tags and fluorescence microscopy in cardiac myocytes and mitochondria harvested from rats receiving 4 weeks ALDOST alone, or in combination with spironolactone or amlodipine cotreatment. Compared to untreated, age-/sex-matched controls, we found (see Fig. 2 [73] . These iterations in divalent cation composition were accompanied by increased levels of 3-nitrotyrosine and 4-hydroxy-2-nonenal in cardiomyocytes, together with increased H 2 O 2 production, malondialdehyde and oxidized glutathione in mitochondria that were coincident with increased activities of Cu/Zn-SOD and glutathione peroxidase (GSH-Px) [59, 66, 73] production, cardiomyocyte xanthine oxidase activity, and cardiac and mitochondrial 8-isoprostane levels, counterbalanced by increased activity of antioxidant proteins, enzymes, and the nonenzymatic antioxidants that can be considered as cumulative antioxidant capacity. Some of these enzymes and proteins (e.g., metallothionein-1, Cu/Zn-superoxide, glutathione synthase) are regulated by MTF-1; and (iii) although these augmented antioxidant defenses were sustained at week 4, overall they fell short in combating the persistent intracellular Ca 
Translational research: divalent cation dyshomeostasis in human CHF
The secondary aldosteronism of CHF is accompanied by ionized hypocalcemia with SHPT [36-38, 45, 81]. As noted earlier, dyshomeostasis of divalent cations frequently occurs in patients hospitalized with decompensated biventricular failure due to a dilated (idiopathic) cardiomyopathy. Elevated serum PTH with SHPT is an established feature of primary and secondary aldosteronism [82] . Increased PTH levels found in patients with primary aldosteronism can be reduced by either an aldosterone receptor antagonist, spironolactone, or by adrenal surgery which also corrects ionized hypocalcemia [82] . SHPT is especially prevalent in African-Americans (AA) with protracted decompensated biventricular failure, where chronic elevations in plasma aldosterone account for symptoms and [38] . This is also related to the prevalence of hypovitaminosis D in AA with CHF [38] . The increased melanin content of darker skin in AA serves as a natural sunscreen. Accordingly, the prevalence of hypovitaminosis D, often of marked severity, compromises Ca 2? homeostasis predisposing AA patients to hypocalcemia and consequent SHPT [38, 83, 84] . Hypomagnesemia is another common clinical feature of aldosteronism, which too is corrected by spironolactone or adrenal surgery [85] [86] [87] . In addition to the ionized hypocalcemia and hypomagnesemia that accompany increased urinary and fecal losses of these divalent cations, other studies have now identified a concomitant dyshomeostasis of Zn 2? with hypozincemia [88, 89] . Urinary Zn 2? excretion is increased in response to angiotensin-converting enzyme inhibitor or angiotensin receptor antagonist [90, 91] .
We documented for the first time serum Zn 2? and Se 2? levels to be reduced in our AA patients followed here in Memphis [36, 37] . This included those with decompensated failure and compensated failure, as well as with heart disease but not heart failure. Reasons for the deficiency of these divalent cations, including their reduced dietary intake, are under investigation. Tennessee soil is not deficient in these minerals. Se is an essential trace mineral and cofactor of antioxidant selenoenzymes, such as GSH-Px and thioredoxin reductase, that promote optimal antioxidant/oxidant balance [92] . Furthermore, a Se-deficient diet is associated with a diminished activation potential of NFjB and downregulation of Se-GSH-Px activity, which detoxifies peroxides and hydroperoxides in such diverse tissues as kidney, cardiovasculature, and red cells [93] [94] [95] [96] [97] [98] , which is readily reversible when dietary Se is adequately fortified [96, 97, 99] . Monitoring serum Se, Se-dependent enzyme activities, and Se-GSH-Px mRNA expression are clinically useful in addressing optimal Se supplementation [100, 101] .
There is an appearance of a dilated cardiomyopathy in greater abundance in general populations where dietary Se 2? deficiencies are found, such as in the Se-poor soil of the Keysan Province of China, or when parenteral nutrition is deficient in Zn and/or Se, [102] [103] [104] . It has been suggested that the myopathic process in these scenarios is more closely related to altered immunocompetence and predisposition to viral pathogens than a direct effect of the specific trace mineral deficiencies on the myopathic heart. However, this is arguable. A redistribution of Se from the vascular compartment into tissues that may occur in chronic illness has also been suggested as contributory to the genesis of a dilated (idiopathic) cardiomyopathy [105] [106] [107] [108] [109] .
Therefore, the metabolic-hormonal profile of CHF with aldosteronism depicts a concerted and contemporaneous dyshomeostasis of multiple nutrients that include Ca 2? , [110] and a preference for a high Na ? diet that enhances urinary Ca 2? excretion. A high-salt diet and consequential calciuria is well known for predisposing a patient to ionized hypocalcemia and SHPT with a resorption of bone which is invoked to restore extracellular Ca 2? homeostasis. Over time, osteopenia and osteoporosis accompany the calciuria of long-term dietary Na
? excess further predisposing them to atraumatic bone fractures [111, 112] . The risk of such fractures is now shown to be increased in patients with heart failure and appears to be preventable by spironolactone together with today's standard of care [113, 114] .
Summary
Previous myocardial infarction, hypertensive heart disease, or a dilated (idiopathic) cardiomyopathy may each contribute to the heart's failure as a muscular pump that is perpetuated by a sporadic and progressive necrosis of cardiomyocytes, replaced by fibrous tissue, and promoted by inappropriate neurohormonal activation and effector hormones of the RAAS and ANS. The hyperadrenergic, acute stressor state in CHF is accompanied by a translocation of K ? , Ca 2? , Mg 2? , and Zn 2? from the vascular to intracellular compartment. In the case of cardiac myocytes and mitochondria, intracellular Ca 2? overload and the induction of oxidative stress leads to mPTP opening, organellar degeneration, cardiomyocyte necrosis with myocardial fibrosis and subsequent scarring. A similar signal-transducer-effector pathway is at play with the chronic stressor state of aldosteronism where inappropriate elevations in plasma aldosterone, together with the heightened excretory losses of Ca 2? and Mg 2? , lead to resultant hypocalcemia and hypomagnesemia and each contributes to the appearance of SHPT. Elevations in plasma PTH seek to restore extracellular homeostasis of these divalent cations through their resorption from bone. At the same time, PTH-mediated intracellular Ca 2? overloading becomes highly prevalent in affected cardiac myocytes and mitochondria. This Ca 2? paradox accounts for an induction of oxidative stress, leading to cardiomyocyte necrosis and subsequent reparative fibrosis. Fibrosis contributes to the adverse structural remodeling of the right and left heart with its attending pathologic influences on myocardial stiffness and contractility while it also serves as substrate for re-entrant arrhythmias. An intrinsically [66, 73] .
Conclusions
In unraveling these intricate cellular and molecular pathways leading to myocardial necrosis and fibrosis, it raises the prospect for nutriceutical uncoupling of Ca 2? and Zn channel blocker. In addressing the importance of a simultaneous dyshomeostasis involving multiple macro-and micronutrients, particularly in African-Americans with CHF, it is plausible to prevent the adverse structural remodeling of myocardium, which inevitably contributes to increased cardiovascular risk. The time is propitious to develop novel strategies that combine current pharmacologic interventions with inexpensive nutriceutical adjuvants to achieve the greatest therapeutic potential in CHF, which is fast becoming the most serious burden to health care cost containment in today's industrialized world. 
